Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells.


  • Antigen-specific T cells can be selectively expanded using the Opto™ Antigen Presenting Bead kit upstream of the Opto™ Cell Therapy Development workflow, enabling you to directly link peptide binding and recognition to antigen specific effector function.

  • The Opto™ Cell Therapy Development worfklow accelerates the creation of better therapeutics by enabling multiple functional assays to be performed simultaneously on 1000s of individual T cells in a matter of days. Deeply characterize, profile, and map your T cell populations at the single-cell level to directly link behavior to gene expression.


  • Polyfunctional T cells are considered the most potent anti-tumor effector T cells. Originally presented in early 2021, this webinar features Dr. Jason McEwen, the Director Biology at Berkeley Lights, as he reviews how to use a multi-omic workflow to find and fully profile polyfunctional T cells for more effective therapies.

  • CAR T therapy in children with leukemia was the first FDA-approved gene modified cell therapy.  Dr. David M Barrett, one of the developers of this therapy, shares new insight into Naïve T cells and how chemotherapy impacts their function.

  • Immunogenicity validation is a critical bottleneck in the tumor antigen discovery process in part because the vast majority of candidate neoantigens identified in a tumor are not recognized by T cells. This product tour shows how the Opto™ Antigen Presenting Bead Kit and Opto™ Cell Therapy Development workflow address this bottleneck.


Berkeley Lights

5858 Horton St, Suite 320

Emeryville, CA 94608


Phone: 510-585-2855

Contact: Anna Quinlan


  • Understanding the genetic mechanisms of T cell polyfunctionality could be critical for developing effective therapeutics. The Opto™ Cell Therapy Development workflow makes it possible to identify these mechanisms by characterizing function at the single-cell level and linking phenotypic data to individual gene expression profiles.

  • To harness their full therapeutic potential, we must understand the relationship between target cell killing and other critical functions of individual T cells. This application note demonstrates how the Berkeley Lights platform can be used to interrogate antigen-specific serial killing activity of single CAR T cells and correlate this to cytokine secretion and proliferation while preserving individual T cells for downstream analyses or expansion.

  • Current experimental methods to characterize NK cells rely on bulk measurements of heterogenous samples that often contain contaminating cell types. In this application note, we demonstrate how NK cell function can be assessed at the single-cell level to characterize both cytotoxicity and ADCC mediation in the presence of target cells.

  • Current techniques used to assess T cell function only allow us to draw correlative conclusions. This application note demonstrates how the Berkeley Lights platform can directly link phenotype to genotype to identify differences in CAR T cell killing kinetics as well as to recover TCR sequences that are associated with desired killing behavior.

  • Many methods to measure single-cell T cell proliferation are time-consuming and can't measure antigen-specific proliferation and correlate that growth to other parameters such as cytokine secretion and cytotoxicity of the same cell. This application note demonstrates how the Berkeley Lights platform can be used to identify single T cells that maintain proliferative ability while secreting specific cytokine combinations and exhibiting desired tumor killing activity.   


  • T cell-based immunotherapy is promising as a treatment for multiple types of cancer but current techniques limit our ability to measure T cell characteristics of interest and select the most efficacious cells for a therapy. New technologies are needed to allow us to identify the drivers of desired phenotypes such as polyfunctionality, serial killing, and proliferation.